These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19169481)

  • 1. Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.
    Coeli FB; Ferraz LF; Lemos-Marini SH; Rigatto SZ; Belangero VM; de-Mello MP
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1277-81. PubMed ID: 19169481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent mineralocorticoid excess (AME) syndrome.
    Parvez Y; Sayed OE
    Indian Pediatr; 2013 Apr; 50(4):416-8. PubMed ID: 23665601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.
    Yau M; Haider S; Khattab A; Ling C; Mathew M; Zaidi S; Bloch M; Patel M; Ewert S; Abdullah W; Toygar A; Mudryi V; Al Badi M; Alzubdi M; Wilson RC; Al Azkawi HS; Ozdemir HN; Abu-Amer W; Hertecant J; Razzaghy-Azar M; Funder JW; Al Senani A; Sun L; Kim SM; Yuen T; Zaidi M; New MI
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11248-E11256. PubMed ID: 29229831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
    Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
    Pizzolo F; Friso S; Morandini F; Antoniazzi F; Zaltron C; Udali S; Gandini A; Cavarzere P; Salvagno G; Giorgetti A; Speziali G; Choi SW; Olivieri O
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1234-41. PubMed ID: 26126204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.
    Yau M; Azkawi HS; Haider S; Khattab A; Badi MA; Abdullah W; Senani AA; Wilson RC; Yuen T; Zaidi M; New MI
    Ann N Y Acad Sci; 2016 Jul; 1376(1):65-71. PubMed ID: 27526338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome.
    Tapia-Castillo A; Baudrand R; Vaidya A; Campino C; Allende F; Valdivia C; Vecchiola A; Lagos CF; Fuentes CA; Solari S; Martínez-Aguayo A; García H; Carvajal CA; Fardella CE
    J Clin Endocrinol Metab; 2019 Feb; 104(2):595-603. PubMed ID: 30239803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
    Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
    J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T; Al-Shaikh A
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB; Stewart PM
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
    Morineau G; Sulmont V; Salomon R; Fiquet-Kempf B; Jeunemaître X; Nicod J; Ferrari P
    J Am Soc Nephrol; 2006 Nov; 17(11):3176-84. PubMed ID: 17035606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
    Fan P; Lu YT; Yang KQ; Zhang D; Liu XY; Tian T; Luo F; Wang LP; Ma WJ; Liu YX; Zhang HM; Song L; Cai J; Lou Y; Zhou XL
    Endocrine; 2020 Dec; 70(3):607-615. PubMed ID: 32816205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Cortisol and Cortisone as Potential Biomarkers of Partial 11β-Hydroxysteroid Dehydrogenase Type 2 Deficiency.
    Carvajal CA; Tapia-Castillo A; Valdivia CP; Allende F; Solari S; Lagos CF; Campino C; Martínez-Aguayo A; Vecchiola A; Pinochet C; Godoy C; Iturrieta V; Baudrand R; Fardella CE
    Am J Hypertens; 2018 Jul; 31(8):910-918. PubMed ID: 29617893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent mineralocorticoid excess syndrome: an overview.
    Palermo M; Quinkler M; Stewart PM
    Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess.
    Lin-Su K; Zhou P; Arora N; Betensky BP; New MI; Wilson RC
    J Clin Endocrinol Metab; 2004 May; 89(5):2024-7. PubMed ID: 15126515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11β-HSD2-Related Hypertension.
    De Santis D; Castagna A; Danese E; Udali S; Martinelli N; Morandini F; Veneri M; Bertolone L; Olivieri O; Friso S; Pizzolo F
    Front Endocrinol (Lausanne); 2021; 12():681974. PubMed ID: 34497581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients.
    Vitellius G; Delemer B; Caron P; Chabre O; Bouligand J; Pussard E; Trabado S; Lombes M
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5205-5216. PubMed ID: 31225872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
    Carvajal CA; Gonzalez AA; Romero DG; González A; Mosso LM; Lagos ET; Hevia Mdel P; Rosati MP; Perez-Acle TO; Gomez-Sanchez CE; Montero JA; Fardella CE
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2501-7. PubMed ID: 12788846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetic defect resulting in mild low-renin hypertension.
    Wilson RC; Dave-Sharma S; Wei JQ; Obeyesekere VR; Li K; Ferrari P; Krozowski ZS; Shackleton CH; Bradlow L; Wiens T; New MI
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10200-5. PubMed ID: 9707624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
    Lavery GG; Ronconi V; Draper N; Rabbitt EH; Lyons V; Chapman KE; Walker EA; McTernan CL; Giacchetti G; Mantero F; Seckl JR; Edwards CR; Connell JM; Hewison M; Stewart PM
    Hypertension; 2003 Aug; 42(2):123-9. PubMed ID: 12860834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.